PDS Biotechnology granted FDA fast track designation for lead candidate PDS0101

PDS Biotechnology

2 June 2022 - PDS Biotech has been granted fast track designation for PDS0101 in combination with Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16 positive head and neck cancer

PDS Biotechnology Corporation today announced that the U.S. FDA has granted fast track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab).

Read PDS Biotechnology press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track